MARKET NEWS

Evonik Strengthens Biotechnology Capabilities for Drug Substance Manufacturing With New Investment in Slovakia
Alcami to Acquire Contract Packaging Organization Tjoapack
MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
Crown Bioscience & Turbine Partner to Connect AI-Driven Prediction With Organoid Validation in Translational Oncology
Gerresheimer & Milliken Partner to Advance Performance & Protection With LeneX UltraGuard Technology
Piramal Pharma Solutions & Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development & Manufacturing
Nemera Announces Construction of a New Production Hall
Ardena Opens New Bioanalytical Laboratory in New Jersey
First Patients Dosed With Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Bio-Rad Extends Range of Anti-Idiotypic Antibodies & Anti-Fc Mutation Antibodies for Bioanalysis & Drug Monitoring

  EXPERT CONTENT & RESOURCES

Ascendia
Portrait of Bryn L. Dubin

America’s Next Healthcare Crisis Is Already Here - And We’re Not Ready

Bryn L. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy. Dubin has federal and state legislative and policy analysis experience.

INTERVIEW - Advancing Regenerative Medicine for Chronic Disease

INTERVIEW - Advancing Regenerative Medicine for Chronic Disease

Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.

eBook: Understanding the Foundation of LNP Formulation Success

eBook: Understanding the Foundation of LNP Formulation Success

Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.

  FEATURED EDITORIAL

  COMPANY PROFILE

Dyhydromatics designs and manufactures advanced ShearJet® high-pressure homogenization systems and partners with clients to integrate and scale high-pressure processes from R&D through commercial production. With a focus on precision, reliability, and exceptional customer service, Dyhydromatics helps global leaders in pharmaceuticals, biotech, chemicals, food, personal care, and more to develop innovative formulations, achieve nanoscale particle size reduction, and scale seamlessly to commercial success. Click here for more.

VIDEOS

 

  WHITEPAPERS & WEBINARS

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 29 – Controlled Release
March 4 – Drug Delivery